CN109071469A - 三环类化合物及其应用 - Google Patents

三环类化合物及其应用 Download PDF

Info

Publication number
CN109071469A
CN109071469A CN201780024783.9A CN201780024783A CN109071469A CN 109071469 A CN109071469 A CN 109071469A CN 201780024783 A CN201780024783 A CN 201780024783A CN 109071469 A CN109071469 A CN 109071469A
Authority
CN
China
Prior art keywords
compound
alkyl
tautomer
pharmaceutically
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780024783.9A
Other languages
English (en)
Other versions
CN109071469B (zh
Inventor
吴凌云
张鹏
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109071469A publication Critical patent/CN109071469A/zh
Application granted granted Critical
Publication of CN109071469B publication Critical patent/CN109071469B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

本发明涉及一系列三环类化合物及其作为1‑磷酸鞘氨醇1亚型(S1P1)的受体激动剂的应用，具体涉及式(Ι)所示化合物、其互变异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201780024783.9A 2016-08-08 2017-08-08 三环类化合物及其应用 Active CN109071469B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016106501686 2016-08-08
CN201610650168 2016-08-08
PCT/CN2017/096368 WO2018028557A1 (zh) 2016-08-08 2017-08-08 三环类化合物及其应用

Publications (2)

Publication Number Publication Date
CN109071469A true CN109071469A (zh) 2018-12-21
CN109071469B CN109071469B (zh) 2022-04-05

Family

ID=61161606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780024783.9A Active CN109071469B (zh) 2016-08-08 2017-08-08 三环类化合物及其应用

Country Status (2)

Country Link
CN (1) CN109071469B (zh)
WO (1) WO2018028557A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
JP7443550B2 (ja) 2020-03-04 2024-03-05 ヒーリオイースト ファーマシューティカル カンパニー リミテッド 三環系化合物及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005290A1 (en) * 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
WO2011060391A1 (en) * 2009-11-13 2011-05-19 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005290A1 (en) * 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
WO2011060391A1 (en) * 2009-11-13 2011-05-19 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Also Published As

Publication number Publication date
CN109071469B (zh) 2022-04-05
WO2018028557A1 (zh) 2018-02-15

Similar Documents

Publication Publication Date Title
JP6802251B2 (ja) 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
BR112020001124A2 (pt) composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto ou do sal farmaceuticamente aceitável do mesmo e método para tratamento de câncer
CN112955459A (zh) 双环肽配体和其用途
CN108349977A (zh) Jak抑制剂
TWI660946B (zh) 作為ｍａｇｌ抑制劑之胺基甲酸１，１，１－三氟－３－羥基丙烷－２－酯衍生物
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
TWI749126B (zh) Cdk4/6抑制劑
CN110248926A (zh) Lsd1抑制剂及其制备方法和应用
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
CN110325517A (zh) 螺环类化合物及其应用
CN106459009A (zh) 丙肝病毒抑制剂及其制药用途
BRPI0906495B1 (pt) compostos derivados de indolil-piridona e composição farmacêutica
ES2874656T3 (es) Compuesto tricíclico y aplicaciones del mismo
CN107531695A (zh) Jak抑制剂
KR101920472B1 (ko) 오렉신 수용체 길항제로서의 피페리딘 유도체
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN108069959A (zh) 一种含氮杂环类化合物、其制备方法、药物组合物及应用
CN116888108B (zh) 新型egfr降解剂
TW201920171A (zh) 作為a2a受體抑制劑的并環類衍生物
CA3035312A1 (en) Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers
CA3201540A1 (en) Aromatic heterocyclic compound, pharmaceutical composition and use thereof
JP2022533147A (ja) 芳香族アミン類のａｒ及びｂｅｔを標的とするタンパク質分解キメラ化合物及び使用
CN102459278A (zh) 取代的-1,3,8-三氮杂螺[4.5]癸烷-2,4-二酮
CN109071469A (zh) 三环类化合物及其应用
TWI706950B (zh) 二氮雜-苯並熒蒽類化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190109

Address after: 050035 Innovation Building, 315 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province, 3rd Floor

Applicant after: Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant before: NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT CO., LTD.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210908

Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 050035 Innovation Building, 315 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province, 3rd Floor

Applicant before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant